SCHEMBL155267

SCHEMBL155267

CN1CC=C(c2ccc(F)cc2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
QDPR P09417 3/20 0.68
SLC6A4 P31645 1/20 0.52
LMNA P02545 1/20 0.51
THRB P10828 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21037762 0.85 QDPR (0.58) QDPRSLC6A4
SCHEMBL7369176 0.84 QDPR (0.72) QDPRSLC6A4
SCHEMBL16915221 0.81 QDPR (0.56) QDPRSLC6A4
SCHEMBL6043136 0.81 QDPR (0.68) QDPRSLC6A4
SCHEMBL8382616 0.81 QDPR (1.00) QDPR
SCHEMBL13898494 0.81 QDPR (0.68) QDPRSLC6A4LMNA
SCHEMBL578138 0.81 QDPR (0.68) QDPRSLC6A4
SCHEMBL1814323 0.81 QDPR (0.68) QDPR
Bromide SCHEMBL11205020 0.81 SLC6A4 (0.50) QDPRSLC6A4
SCHEMBL8915112 0.80 QDPR (0.62) QDPR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3562822-B1 POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS MITOBRIDGE INC (US) 2021-03-10 EP disclosed
EP-2686305-B1 QUINAZOLINEDIONES AND THEIR USE IMPACT THERAPEUTICS INC (CN) 2020-09-16 EP disclosed
WO-2018125961-A1 POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS MITOBRIDGE, INC. (US) 2018-07-05 WO disclosed
WO-2018044136-A1 NOVEL COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH POLY(ADP-RIBOSE) POLYMERASE-1 (PARP-1) 충남대학교 산학협력단 2018-03-08 WO disclosed
US-9701689-B2 Substituted pyridines and pyridazines as CCR10 receptor inhibitors KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-07-11 US disclosed
US-9701689-B2 Substituted pyridines and pyridazines as CCR10 receptor inhibitors KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-07-11 US disclosed
US-20150299214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND KYOWA HAKKO KIRIN CO., LTD. (JP) 2015-10-22 US disclosed
US-20150299214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND KYOWA HAKKO KIRIN CO., LTD. (JP) 2015-10-22 US disclosed
US-9090568-B2 Quinazolinediones and their use IMPACT THERAPEUTICS, INC. (CN) 2015-07-28 US disclosed
EP-2206714-B1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO LTD (JP) 2015-01-21 EP disclosed
US-20090069299-A1 Pyrazolo[3,4-c]Quinolines, Pyrazolo[3,4-c]Naphthyridines, Analogs Thereof, and Methods COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-03-12 US disclosed
US-20090069299-A1 Pyrazolo[3,4-c]Quinolines, Pyrazolo[3,4-c]Naphthyridines, Analogs Thereof, and Methods COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-03-12 US disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
WO-2007026959-A2 DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-03-08 WO disclosed
WO-2002032870-A1 PROCESS OF THE PREPARATION OF 3-SUBSTITUTED-4-ARYL PIPERIDINE COMPOUNDS SMITHKLINE BEECHAM P.L.C. (GB) 2002-04-25 WO disclosed
WO-2001002357-A2 PROCESS FOR THE SYNTHESIS OF 4-(4'-FLUOROPHENYL)-PIPERIDINES SMITHKLINE BEECHAM P.L.C. (GB) 2001-01-11 WO disclosed
US-6172233-B1 Process for making paroxetine SMITHKLINE BEECHAM PLC (GB) 2001-01-09 US disclosed
US-5945421-A TREATING PSYCHOSIS AND SCHIZOPHRENIA WARNER-LAMBERT COMPANY (US) 1999-08-31 US disclosed
US-4132710-A DIURETICS, ANOREXICS, ANTIDEPRESSANTS, ANTICONVULSANTS, & ANTIHYPERTENSIVE AGENTS AYERST, MCKENNA AND HARRISON, LTD. (CA) 1979-01-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND ARG1, H1-0, TYR QDPR 1610/4885SLC6A4 1572/4885LMNA 560/4885
US-20090069299-A1 Pyrazolo[3,4-c]Quinolines, Pyrazolo[3,4-c]Naphthyridines, Analogs Thereof, and Methods IL4, IL2, IL5 QDPR 79/4885SLC6A4 3645/4885LMNA 2914/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 QDPR 473/4885SLC6A4 3312/4885LMNA 4860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.